In trial of 173 enrolled patients with acute liver failure (not attributed to acetaminophen), they were randomized to placebo or IV N-acetylcysteine (NAC). Although overall survival at 3 weeks was similar between the groups, transplant free survival was significantly higher at 1 year in the NAC group (40% vs 27%), although the benefit was found only in patients with mild encephalopathy (abstract). NAC is beneficial in patients with early stage, non-acetaminophen liver failure.
Share This Post
Categories
Related Posts
Do you have a stack of journals piling up on your desk, beside your bed or in your email inbox? In 1950, medical knowledge was estimated to double every 50 years, but now the doubling time is every few months. At this rate, it is impossible to keep up with the literature, but a group […]
This large systematic review found rectal NSAIDs significantly reduced the risk of post-ERCP pancreatitis compared to pancreatic duct stents (abstract).
This large population-based cohort found the most common causes of drug induced liver injury to be augmentin and diclofenac, followed by herbal and nutritional supplements (abstract).
Leave A Comment